Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia

D. W. Visscher, F. H. Sarkar, T. C. Kasunic, K. B. Reddy

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


We observed no association between neoplastic epithelial immunostaining for either amphiregulin (AR) or heregulin (HRG) and presence of ER, EGFR/ERBB-2 overexpression, nodal status, or disease recurrence in 34 breast carcinomas. However, stromal cell staining for both correlated with outcome; 29% of stromal cell AR+ cases recurred vs. 85% for AR+ cases (p = 0.001), and 41% of stromal cell HRG- cases recurred vs. 82% of HRG+ cases (p = 0.01). We conclude that both HRG and AR have significant biologic roles in breast carcinoma growth or progression via mediation of host-tumor interactions which favor aggressive tumor behavior.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalBreast Cancer Research and Treatment
Issue number1
StatePublished - 1997


  • Amphiregulin
  • Breast carcinoma
  • Epidermal growth factor receptor
  • Heregulin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia'. Together they form a unique fingerprint.

Cite this